3.4.21.46: complement factor D
This is an abbreviated version!
For detailed information about complement factor D, go to the full flat file.
Word Map on EC 3.4.21.46
-
3.4.21.46
-
angiogenesis
-
angiogenic
-
vessel
-
metastasis
-
neovascularization
-
hypoxia
-
artery
-
hypoxia-inducible
-
necrosis
-
retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
-
vein
-
capillary
-
factor-1
-
huvecs
-
vegfr-2
-
collagen
-
vasculature
-
retinopathy
-
eyes
-
ovarian
-
macular
-
tumour
-
tube
-
microvascular
-
mesenchymal
-
anti-vegf
-
lymphatic
-
receptor-2
-
pro-angiogenic
-
bfgf
-
intravitreal
-
progression-free
-
edema
-
choroid
-
metalloproteinase
-
endothelium
-
hypertension
-
sprout
-
matrigel
-
paracrine
-
lymph
-
hif-1alpha
-
mmp-9
-
sunitinib
-
drug development
-
sorafenib
-
vitreous
-
medicine
- 3.4.21.46
- angiogenesis
-
angiogenic
- vessel
- metastasis
- neovascularization
- hypoxia
- artery
-
hypoxia-inducible
- necrosis
- retinal
-
antiangiogenic
-
umbilical
-
bevacizumab
-
microvessels
- vein
- capillary
- factor-1
- huvecs
- vegfr-2
- collagen
- vasculature
- retinopathy
- eyes
- ovarian
-
macular
- tumour
- tube
-
microvascular
- mesenchymal
-
anti-vegf
- lymphatic
- receptor-2
-
pro-angiogenic
- bfgf
-
intravitreal
-
progression-free
- edema
- choroid
- metalloproteinase
- endothelium
- hypertension
-
sprout
- matrigel
-
paracrine
- lymph
- hif-1alpha
- mmp-9
- sunitinib
- drug development
- sorafenib
- vitreous
- medicine
Reaction
selective cleavage of Arg-/-Lys bond in complement factor B when in complex with complement subcomponent C3b or with cobra venom factor =
Synonyms
28 kDa protein, adipocyte, Adipsin, alternative complement pathway component Factor D, C3 convertase activator, C3 proactivator convertase, CFD, complement factor D/adipsin and kallikrein-like serine protease, convertase, C3 proactivator, Df, Df protein, endogenous vascular elastase, esterase, properdin factor D, factor D, factor D (complement), fD, PDGF-D, platelet-derived growth factor D, PoDAK, vascular endothelial growth factor, vascular endothelial growth factor D, VEGF-D
ECTree
Advanced search results
Crystallization
Crystallization on EC 3.4.21.46 - complement factor D
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
in complex with inhibitors, sitting drop vapor diffusion method, using 25% (w/v) PEGME 3350, 100 mM Bis-Tris pH 5.5 or 30% (w/v) PEG MME 2000, 0.1 M thiocyanate
in complex with inhibitors, vapor diffusion method, using 22 or 27% (w/v) PEG3350, 50 mM NaCl and 100 mM HEPES/NaOH, pH 7.5 at 20°C
purified enzyme in complex with anti-factor D Fab fragment, sitting drop vapor diffusion method, 30 mg/ml protein in 20 mM HEPES, pH 7.2, and 200 mM NaCl, is mixed with an equal volume of crystallization buffer containing 0.1 M Tris-HCl, pH 8.5, 0.2 M ammonium phosphate, 50% 2-methyl-2,4-pentanediol, and 0.01 M hexamine cobalt(III) chloride, 6 days, 4°C, X-ray diffraction structure determination and analysis at 2.4 A resolution
structure of native factor D and a complex formed with isatoic anhydride inhibitor
wild-type enzyme, mutants R202A and S81Y/T198S/S199W, and enzyme mutant S183A in ternary complex with C3bB, hanging drop vapour diffusion technique, mixing of 10 mg/ml protein solution with reservoir solution consisting of 15% w/v PEG 6000, 50 mM MES-NaOH pH 6.0, 18°C, 6 days, X-ray diffraction structure determination and analysis at 1.8 A, 2.8 A, 2.0 A, and 3.5 A resolution, respectively, molecular replacement and ensemble refinement
purified enzyme in complex with anti-factor D Fab fragment, sitting drop vapor diffusion method, 20 mg/ml protein in 20 mM HEPES, pH 7.2, and 200 mM NaCl, is mixed with an equal volume of crystallization buffer containing 0.1 M MES, pH 6.5, 25% PEG monomethyl ether 550, 0.01 M zinc sulfate, and 3% 6-aminohexanoic acid, 1 day, 19°C, X-ray diffraction structure determination and analysis at 2.3 A resolution
-